Nucleus Software Q2 FY27: consolidated profit slips 19% YoY to ₹21.3 Cr, margins compress
PAT -19.17% YoY · revenue +6.65% · margins compressing
₹227.7 Cr
+6.65% YoY
₹21.25 Cr
-19.17% YoY
8.72%
-2.7pp YoY
₹8.08
Nucleus Software's consolidated revenue grew 6.65% YoY to ₹227.70 Cr (also +8.21% QoQ from ₹210.43 Cr), but PAT fell 19.2% YoY to ₹21.25 Cr and 11.0% QoQ from ₹23.87 Cr — profit declining even as the topline advanced, so the YoY read is a soft print despite growth. No analyst consensus for this specific quarter turned up in a web search, so the result cannot be graded against street expectations (vsStreet: unknown). Management also gave no numeric revenue or margin guidance on the Q1 FY27 call — only qualitative commentary around a growing order book — so there is no formal guidance bar to measure this print against either.
Q2 FY-2027 vs prior quarters
Net margin (PAT/total income) compressed to 8.72% from 11.45% a year ago and 10.46% last quarter. Employee costs, the dominant cost line, rose to 72.1% of revenue from 69.1% YoY (₹164.2 Cr vs ₹147.5 Cr) — though they eased from Q1's elevated 74.7% — while operating & other expenses crept up to 20.9% of revenue from 19.9% YoY. The squeeze is purely operating: this quarter carried zero exceptional items, so Q1 FY27's reported ₹30.1 Cr PBT (inflated by the one-off gratuity/leave gain) is not comparable to this quarter's clean ₹26.20 Cr. PBT itself fell a sharper 26.0% YoY; a lower effective tax rate (18.9% vs 25.8% a year ago) cushioned the PAT decline to 19.2%.
The stock went into the print at ₹656, down 0.3% over the past month of trading.
For context: revenue is at a 6-quarter high.
No numeric revenue guidance provided. Management emphasized ₹1,244 Cr order book (vs ₹1,044 Cr prior Q) will drive future revenue over multi-year implementation cycles. Targeting high-margin deals in Middle East & Southeast Asia. AI productivity benefits expected in future, not yet quantified.
Standalone PAT fell steeper, -31.3% YoY to ₹19.12 Cr, versus consolidated's smaller -19.2% YoY decline — a divergence of over 10 points, meaning the overseas subsidiaries held up better than the parent this quarter. Segment-wise, revenue growth was led by India (+6.5% YoY to ₹130.5 Cr) and Middle East (+6.6% YoY to ₹28.2 Cr), the latter consistent with management's stated focus on high-margin Middle East/Southeast Asia deals from the Q1 call — though that growth has not yet shown up in consolidated margins. Separately, the company disclosed a ₹17.49 Cr GST show-cause notice on September 29, 2026, a contingent liability not reflected in this quarter's nil exceptional-items line.
W1
Employee-cost ratio trajectory: eased to 72.1% of revenue this quarter from Q1's 74.7%, but still above last year's 69.1% — watch for continued normalization in Q3 FY27
W2
Resolution/provisioning of the ₹17.49 Cr GST show-cause notice (received Sep 29, 2026)
W3
Whether the ₹1,244 Cr order book flagged on the Q1 FY27 call (up from ₹1,044 Cr) converts into revenue and margin recovery, not just topline growth
Standalone is audited; consolidated carries only a limited-review (unaudited) opinion — set period.audited=false for the primary (consolidated) basis. No exceptional items this quarter (unlike Q1 FY27's ₹9.82 Cr one-off gratuity/leave-liability gain); arithmetic ties out exactly on both statements.
Informational and educational content only. Not investment advice.